Development of an active site peptide analog of α-fetoprotein that prevents breast cancer

12Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Epidemiologic studies associate elevated maternal serum levels of a-fetoprotein (AFP) with reduced breast cancer risk for parous women. Laboratory studies demonstrate direct anti-breast cancer activity of AFP. Here, we review the development of a small cyclic peptide that is an active site analog of AFP, referred to as AFPep, which is composed exclusively of amino acids, is orally active, has no discernable toxicity, and is effective for the treatment and prevention of breast cancer in animal models. ©2014 AACR.

Cite

CITATION STYLE

APA

Jacobson, H. I., Andersen, T. T., & Bennett, J. A. (2014). Development of an active site peptide analog of α-fetoprotein that prevents breast cancer. Cancer Prevention Research. American Association for Cancer Research Inc. https://doi.org/10.1158/1940-6207.CAPR-13-0405

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free